Common Stock, $0.0001 par value per share
- Symbol
- NSPR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 8.01, 9.01 · 8-K
InspireMD Inc.
NSPRNASDAQEQUITYCurrent
Regulation FD Disclosure · Other Events
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description Number ────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release, dated November 12, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Press release in this filing
InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System →Company context
InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.
Current securities
Registered securities in this filing
InspireMD, Inc. · 8-K · Filed 2026-11-12
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit Description
Number
──────────────────────────────────────────────────────────────────────────────────────
99.1 Press Release, dated November 12, 2026
104 Cover
Page Interactive Data File (embedded within the Inline XBRL document)
Filed exhibits (1)
Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR procedures annually - - Approval supported by CGUARDIANS II pivotal trial data, which demonstrated 100% acute device success and zero death, stroke, myocardial infarction or stent thrombosis reported at 30 days - Miami, FL - November 12, 2026 - InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Premarket Approval (“PMA”) Supplement for the CGuard ® Prime TransCarotid Stent System for use in transcarotid artery revascularization (“TCAR”) procedures. The approval allows physicians in the U.S. to use the CGuard ® Prime TransCarotid Stent System, which features an 80 cm delivery system, in transcarotid artery revascularization (“TCAR”) procedures when used in conjunction with an embolic protection system specified in th…
Open exhibit ↗